Besides their direct inhibitory effect on angiogenesis, anti-angiogenic agents can reverse tumor-related immune suppression through several mechanisms, such as the decrease of immunosuppressive cells (MDSCs, regulatory T cells) and cytokines (TGFβ and IL-10) and the direct inhibiting interaction on PD-1 on T cells [60]. This evidence concerns the gene RPL17 and neoplasm.